Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502362-24-00

Acronym

21-API-03

Enrollment

170

Registered

2025-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erosive osteoarthritis

Brief summary

Structural damage is assessed using the Verbruggen-Veys score. The evolution of structural damage between M0 and M12, or worsening, of digital osteoarthritis of a joint will be defined by the change in stage of the Verbruggen-Veys score by at least one level

Interventions

DRUGMETOJECT 15 mg / 0

DRUG30 ml

DRUGsolution injectable en stylo prérempli

DRUGSPECIAFOLDINE 5 mg

DRUGcomprimé

DRUGSODIUM CHLORIDE SOLUTION 0.9%

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Structural damage is assessed using the Verbruggen-Veys score. The evolution of structural damage between M0 and M12, or worsening, of digital osteoarthritis of a joint will be defined by the change in stage of the Verbruggen-Veys score by at least one level	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026